|
Eisai Enters into Partnership with PharmaSwiss for Halaven (Eribulin) Promotion and Distribution in Central and Eastern European Countries
Eisai (JCN Newswire)
2012-04-05 Tokyo, Apr 5, 2012 - ( JCN Newswire ) - Eisai Co. Ltd announced today that its U.K. subsidiary Eisai Europe Limited has entered into an agreement with PharmaSwiss S.A., a Division of Valeant Pharmaceuticals International, Inc., to promote and distribute the company's novel anticancer agent Halaven (eribulin mesylate) in a number of Central and Eastern European (CEE) countries.
Discovered and developed by Eisai, Halaven is the first single-agent chemotherapy to demonstrate a statistically significant overall survival benefit in patients with pretreated metastatic breast cancer. The agent was approved by the European Commission in March 2011 for the treatment of patients with locally advanced or metastatic breast cancer whose disease has progressed after at least two chemotherapeutic regimens for advanced disease, including an anthracycline and a taxane, and is now available in 11 European countries
Under the terms of the agreement, PharmaSwiss will promote and distribute Halaven in Bulgaria, Estonia, Latvia, Lithuania, Poland, Romania, Hungary and Slovenia. PharmaSwiss is the largest distributor in CEE, offering regional expertise in such functions as regulatory, compliance, sales, marketing and distribution. This new partnership will enable Eisai to deliver its innovative, novel drug Halaven much faster to patients in these CEE countries in which the company has not established locally based sales offices.
Eisai is committed to increasing access to its medicines through the implementation of various new partnership-based business models to improve affordability, availability and adoption, and to making contributions to increase the benefits provided to an even greater number of patients and families worldwide.
AboutEisai
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.co.jp/index-e.html
|
|
|
